305 related articles for article (PubMed ID: 21617789)
41. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
42. Aromatase inhibitors and arthralgia.
Donnellan PP; Douglas SL; Cameron DA; Leonard RC
J Clin Oncol; 2001 May; 19(10):2767. PubMed ID: 11352973
[No Abstract] [Full Text] [Related]
43. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
44. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Sestak I; Sapunar F; Cuzick J
J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
[TBL] [Abstract][Full Text] [Related]
45. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Clemons M; Coleman RE; Verma S
Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
[TBL] [Abstract][Full Text] [Related]
46. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Smith IE; Yeo B; Schiavon G
Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
[TBL] [Abstract][Full Text] [Related]
47. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Hutchinson L
Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
[No Abstract] [Full Text] [Related]
48. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
49. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
50. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
51. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
52. Getting a grip on aromatase inhibitor-associated arthralgias.
Hershman DL
J Clin Oncol; 2008 Jul; 26(19):3120-1. PubMed ID: 18474872
[No Abstract] [Full Text] [Related]
53. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
54. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
55. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
56. Tamoxifen therapy for patients with breast cancer.
Litton J; Buzdar A; Mac Gregor MC; Gonzalez-Angulo A; Hortobagyi G
Lancet; 2013 Jun; 381(9883):2077-8. PubMed ID: 23769223
[No Abstract] [Full Text] [Related]
57. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
58. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
59. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Ewer MS; Glück S
Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Köberle D; Thürlimann B
Breast; 2005 Dec; 14(6):446-51. PubMed ID: 16169728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]